Cadence Biomedical, Seattle, Washington, announced the closing of an oversubscribed (there are more requests to purchase securities than there are securities available for sale) $1.1 million Series A2 financing led by HealthTech Capital, Los Altos Hills, California. The financing will support manufacturing and sales as Cadence releases its Kickstart™ Kinetic Orthosis to the market.
“The close of this financing represents a significant milestone in the history of Cadence,” said Cadence CEO Brian Glaister. “We are pleased with the syndicate of investors who have joined in this round and are excited to work with these new partners as we release Kickstart to the market.”
Cadence Biomedical has previously been awarded grants from the National Institutes of Health (NIH) and the Congressionally-Directed Medical Research Program.
To ready more about the Kickstart, click here.
